Dr. Brian D. Hale, MD

Dr. Hale practices at Advanced Urology Institute in Oxford, Florida.

Dr. Hale's NPI, 1457355059, was assigned on June 10, 2005. Dr. Hale graduated from Emory School of Medicine in 1989. Dr. Hale holds Florida license ME67771.

Dr. Hale's primary practice is Advanced Urology Institute, at 12109 County Rd 103, Oxford, FL 34484 in Sumter County. The practice phone is (352) 391-6494.

Dr. Hale's primary practice is Advanced Urology Institute in Oxford, Florida. Dr. Hale is also affiliated with BayCare St. Joseph's Hospital. The medical group on file is Advanced Urology Institute. Dmand AI also links Dr. Hale to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hale practices, 7 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Hale's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Hale is board certified in urology by the American Board of Urology. Dmand AI has Dr. Hale's licenses on file in 2 states: Florida and Georgia.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), kidney cysts, kidney removal surgery, kidney stone disease, prostate cancer and prostate inflammation or infection among the conditions Dr. Hale treats.

CMS data shows 5,625 Medicare services from Dr. Hale across 25 procedure codes in 2024, for 755 Medicare patients. Medicare paid $250,895 for them.

CMS counts 755 Medicare patients who saw Dr. Hale in 2024. The largest group is 75 to 84, with 334 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hale's median patient age at 70, with 21% women.

In 2024, Dr. Hale wrote 3,174 Medicare Part D claims for 814 patients. 92% of them were for generic drugs. CMS names the drug for 3,054 of them, across 26 drugs with 11 or more claims each, at $996,886 in total drug cost. In 2023, CMS named 3,017 claims across 26 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Hale for performance year 2024, reported as part of a group. Dr. Hale accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hale as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 1 paper to Dr. Hale in 2020. Dr. Hale's most frequent co-authors are Ammar Mohammad Athar, MD, Alan Bruce Schliftman, MD and Corey S. Scurlock, MD.

Dmand AI links Dr. Hale to 1 clinical trial. Conditions studied include Urinary Retention and Urination Disorders. Open Payments lists research payments to Dr. Hale that name 1 trial.

CMS Open Payments shows 376 general payments to Dr. Hale from 54 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 92% of the total. Dendreon Pharmaceuticals LLC paid the most, $1,469. It also lists 2 research payments totaling $22,586 from 2017 to 2018, naming 1 clinical trial.

Dr. Hale graduated from Emory School of Medicine in 1989.

Dr. Hale is in network with 17 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.